Solid Tumors2021-12-17T11:41:57+01:00

ASCO Solid Tumors 2021 – virtual


Lecture Board: Todd M. Bauer, MD; Zineb Belcaid, MD; Ian Chau, MD; Hyun C. Chung, MD; Thorsten O. Götze, MD; Christian Schauer, MD

Medical Writer: Florence Boulmé, PhD

Preface ASCO Solid Tumor 2021

Preface ASCO Solid Tumor 2021 Ian Chau, MD, Department of Medicine, The Royal Marsden Hospital, Sutton, Surrey, United Kingdom Dear Colleagues, Because of the ongoing COVID-19 pandemic, this year’s ASCO scientific meeting took place for the second time virtually from Friday, June 04, through Monday, June 08.

Novel approaches in gastric cancer

Novel approaches in gastric cancer LEAP-005: lenvatinib plus pembrolizumab in gastric cancer With more than 1 million newly diagnosed cases in 2020, gastric cancer was at the fifth place (5.6 %) of the most frequent malignant diseases and accounted for nearly 8 % of cancer deaths worldwide [1].

Checkpoint inhibition: predictors, resistance and immunogenomic features

Checkpoint inhibition: predictors, resistance and immunogenomic features Predictors of immunotoxicity to checkpoint inhibitors Immune checkpoints, such as cytotoxic T-lymphocyte associated protein-4 (CTLA-4) or programmed cell death protein 1 (PD-1), downregulate T-cell responses and are crucial for self-tolerance, which protects the body against attacking cells indiscriminately [1].

Early insights for CPI combinations in solid tumors

Early insights for CPI combinations in solid tumors Ezabenlimab combined with anti-VEGF/Ang2 inhibitor Immunotherapy using anti-PD-1 immune checkpoint inhibitors (CPIs), which is a major therapeutic option in oncology, can potentially achieve synergistic effects once combined with targeted therapies [1].


All downloads from ASCO 2021 – solid tumors

ASCO Solid Tumors 2021 English Download

Full report (english)


All videointerviews from ASCO Solid Tumors 2021

Peter R. Galle overviews the role of immunotherapy in the setting of hepatocellular carcinoma as well as biomarker-based patient selection and discusses which novel combinations of immune checkpoint inhibitors with other drug classes are most promising at present and how those novel strategies impact the treatment landscape.

Roberto Pazo-Cid outlines recent insights gained in terms of anti-PD-1 treatment in the setting of esophageal squamous cell carcinoma, talks about the practice-changing results obtained in the CheckMate 649 trial and the impact of PD-1 inhibition on the real-world prognosis of patients with gastric and esophageal adenocarcinoma as well as further developments regarding immune checkpoint inhibition.

A range of relevant and potentially practice-changing findings was presented in the field of lung cancer. Immunotherapy and targeted-therapy strategies are now being explored either before or after surgery for early stage disease, with multiple challenges in determining what is and is not a transformative approach. (ASCO 2020)

D. Ross Camidge • MD • PhD, Director of Thoracic Oncology, University of Colorado, Aurora, Colorado, USA National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC)